Phase II Trial of Preoperative Irinotecan-Cisplatin Followed by Concurrent Irinotecan-Cisplatin and Radiotherapy for Resectable Locally Advanced Gastric and Esophagogastric Junction Adenocarcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 5, 2009, Pages 1430-1436

  Rivera, Fernando ^a   Galán, Maica ^b   Tabernero, Josep ^c   Cervantes, Andres ^d   Vega Villegas, M Eugenia ^a   Gallego, Javier ^e   Laquente, Berta ^b   Rodríguez, Edith ^d   Carrato, Alfredo ^e   Escudero, Pilar ^f   Massutí, Bartomeu ^g   Alonso Orduña, Vicente ^h   Cardenal, Adelaida ^a   Sáenz, Alberto ^f   Giralt, Jordi ^c   Yuste, Ana Lucia ^g   Antón, Antonio ^h   Aranda, Enrique ⁱ  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITY OF VALENCIA   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^h HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

ⁱ HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Cisplatin; Gastric cancer; Irinotecan; Preoperative chemoradiotherapy

Indexed keywords

CARDIOTOXICITY; CHEMORADIOTHERAPY; CIS-PLATIN; GASTRIC CANCERS; IRINOTECAN; MEDIAN SURVIVAL; NEUTROPENIA; PATHOLOGIC COMPLETE RESPONSE (PCR); PHASE II; SURGICAL RESECTION; SURVIVAL RATE;

RADIOTHERAPY; TOXICITY;

PLATINUM COMPOUNDS;

CISPLATIN; IRINOTECAN;

ADENOCARCINOMA; ANEMIA; ARTICLE; ASTHENIA; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA; FEBRILE NEUTROPENIA; GASTRECTOMY; HUMAN; LOWER ESOPHAGUS SPHINCTER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PREOPERATIVE PERIOD; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VOMITING;

ADENOCARCINOMA; ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; HUMANS; PREOPERATIVE PERIOD; PROSPECTIVE STUDIES; REMISSION INDUCTION; SPAIN; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 71649083039     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.12.087     Document Type: Article

References (21)

1. Ferlay J., Autier P., Boniol M., et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18 (2007) 581-592
2. Brennan M.F. Karpeh MS Jr. Surgery for gastric cancer: The American view. Semin Oncol 23 (1996) 352-359
3. Macdonald J.S., Smalley S.R., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345 (2001) 725-730
4. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for respectable gastroesophageal cancer. N Engl J Med 355 (2006) 11-20
5. Boige V., Pignon J., Saint-Aubert B., et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial (Abstr.). J Clin Oncol 25 Suppl (2007) 200s
6. Roth A.D., Allal A.S., Brundler M.A., et al. Neoadjuvant radiochemotherapy for locally advanced gastric cancer: A phase I-II study. Ann Oncol 14 (2003) 110-115
7. Lowy A.M., Feig B.W., Janjan N., et al. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol 8 (2001) 519-524
8. Ajani J.A., Mansfield P.F., Janjan N., et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 22 (2004) 2774-2780
9. Ajani J.A., Mansfield P.F., Crane C.H., et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: Degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 23 (2005) 1237-1244
10. Ajani J.A., Winter K., Okawara G.S., et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): Quality of combined modality therapy and pathological response. J Clin Oncol 24 (2006) 3953-3958
11. Rohatgi P.R., Mansfield P.F., Crane C.H., et al. Surgical pathology stage by American Joint Commission on Cancer Criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer 107 (2006) 1475-1482
12. Ajani J.A. Evolving chemotherapy for advanced gastric cancer. Oncologist 10 Suppl. 3 (2005) 49-58
13. Ilson D.H., Saltz L., Enzinger P., et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 17 (1999) 3270-3275
14. Ilson D.H., Bains M., Kelsen D.P., et al. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol 21 (2003) 2926-2932
15. Mandard A.M., Dalibard F., Mandard J.C., et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Cancer 73 (1994) 2680-2686
16. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10 (1989) 1-10
17. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
18. Brookmeyer R., and Crowley J. A confidence interval for the median survival time. Biometrics 38 (1982) 29-41
19. Pozzo C., Barone C., Szanto J., et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: Results of a randomized phase II study. Ann Oncol 15 (2004) 1773-1781
20. Dank M., Zaluski J., Barone C., et al. Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st-line advanced gastric cancer patients (Abstr.). J Clin Oncol 23 Suppl (2005) 308s
21. Tew W.P., Minsky B., Bains M., et al. Phase II trial of preoperative combined modality therapy for esophageal carcinoma: Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy (Abstr.). J Clin Oncol 23 Suppl (2005) 312s